Gly-Arg-Gly-Asp-Ser (TFA)

CAS No.

Gly-Arg-Gly-Asp-Ser (TFA) ( )

Catalog No. M30281 CAS No.

Gly-Arg-Gly-Asp-Ser (GRGDS) is a cell binding protein domain derived from the cell-binding region of fibronectin. Osteopontin uses this motif for cell adhesion.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote

Biological Information

  • Product Name
    Gly-Arg-Gly-Asp-Ser (TFA)
  • Note
    Research use only, not for human use.
  • Brief Description
    Gly-Arg-Gly-Asp-Ser (GRGDS) is a cell binding protein domain derived from the cell-binding region of fibronectin. Osteopontin uses this motif for cell adhesion.
  • Description
    Gly-Arg-Gly-Asp-Ser (GRGDS) is a cell binding protein domain derived from the cell-binding region of fibronectin. Osteopontin uses this motif for cell adhesion.
  • Synonyms
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    IC50: 5 μM (αvβ3), 6.5 μM (αvβ5)
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    --
  • Formula Weight
    604.5
  • Molecular Formula
    C19H31F3N8O11
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

Kim GH, et al. Evaluation of Osteoblast-Like Cell Viability and Differentiation on the Gly-Arg-Gly-Asp-Ser Peptide Immobilized Titanium Dioxide Nanotube via Chemical Grafting. J Nanosci Nanotechnol. 2016 Feb;16(2):1396-9.
molnova catalog
related products
  • Dehydropipernonaline

    Dehydropipernonaline is a useful organic compound for research related to life sciences.

  • Setipiprant

    Setipiprant is an orally available, selective CRTH2 antagonist (IC50: 6.0 nM). CRTH2 is a G protein-coupled receptor for prostaglandin (PGD2).

  • NSC756093

    NSC756093 potentially inhibits GBP1:PIM1 interaction. NSC756093 can be used in ovarian cancer studies.